Oxaliplatin for injection

DRUG3 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Conditions

Intrahepatic CholangiocarcinomaOvarian CancerResectable Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 1

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

RecruitingNCT06840002

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Ovarian Cancer

Start: 2025-03-18End: 2026-07-31Target: 150Updated: 2025-09-30

Phase 2

Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Not yet recruitingNCT07643623

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Start: 2026-06-15End: 2031-12-31Target: 720Updated: 2026-06-11

Phase 3

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

RecruitingNCT05342194

Shanghai Junshi Bioscience Co., Ltd.Intrahepatic Cholangiocarcinoma

Start: 2023-06-19End: 2027-05-31Target: 480Updated: 2025-04-23

Related Papers

Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study

Journal of Immunotherapy and Precision Oncology2025-01-141 citations

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

Signal Transduction and Targeted Therapy2023-03-17132 citations